Phenoxodiol-Topotecan combination therapy allows the administration of both agents at lower doses while retaining significant anti-tumor activity compared to monotherapy. These findings suggest that the Phenoxodiol-Topotecan combination may represent an alternative treatment modality for the management of ovarian cancer and justifies further investigation in the clinical setting.
No takes yet. Share an insight, caveat, or question.
Alvero et al. (2007) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: